Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation
1 clinical trials · Condition
◉ Watch Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation
| Record | Firm | Date |
|---|---|---|
| A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) (NCT02259114) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-10-23 |
Track Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation automatically
Every clearance here is in the API, with alerts when new ones post.